WHAT’S NEXT FOR POST-ACUTE MARKETS?
Convalescing From COVID: The Road Ahead For Post-Acute Providers
Mark Parkinson, President & CEO,
American Health Care Association (AHCA)
COVID-19 has been especially brutal for nursing homes. People in long-term care facilities have accounted for less than 10% of all coronavirus cases but 45% of COVID-19 deaths – 70,000 patients and staff as of mid-August. Find out what it will take for nursing facilities to recover, and what the industry may look like when the pandemic is over.
- How nursing homes can weather the negative financial impacts of COVID-19
- What types of providers are most at risk
- How their business partners can help
How The COVID Experience Will Change Post-Acute Providers’ Supply Chain Strategies
Steven LaForte, Director of Corporate Affairs, General Counsel,
Luis Martinez, VP, Supply Chain,
Most nursing homes and other long-term care facilities had fairly simple supply chain needs and structures prior to the pandemic – many didn’t even have so much as a purchasing agent. COVID-19 hit hard, and these facilities needed PPE and other products they’d never used before and couldn’t easily acquire. In this session, consider:
- How the supply chain will reorganize to better serve post-acute providers
- What manufacturers and distributors can do to best support this market
- Where the greatest challenges and opportunities lie
The Future For Home Health And Hospice
Sherill Mason, Principal,
Mason Advisors, LLC
Three months into the pandemic, 90% of home health agencies reported a decline in admissions and revenue. Some clients paused services because family members were able to provide care while working from home; others refused to allow caregivers into the home for risk of exposure. Many hospice organizations were similar affected.
- Understand how well and how quickly home health and hospice providers are recovering
- Find out how their menu of services is evolving to better support current customer concerns and needs
- Discuss the role of supply chain partners in home care’s post-pandemic success
WHAT’S NEXT FOR LAB AND DIAGNOSTICS?
Elevating Diagnostics in the Post-COVID Healthcare Environment
Robert Michel, Editor-in-Chief,
DARK Daily and the Dark Report
A year ago, lab testing was the behind-the-scene factor driving the vast majority of medical decisions. As the pandemic progressed, diagnostics moved front-and-center, with policymakers, media, and consumers discussing the merits of different methodologies and the importance of expanded testing.
- How can the diagnostics industry leverage its greatly increased visibility?
- How might the COVID experience impact product approvals, reimbursement, and other key policy decisions in the future?
COVID Testing: What's Happening Now, And What's Ahead
Mike Abney, SVP Distribution Strategy,
Jim Poggi, Director, Vendor Relations,
Nathan Patton, Sr. Director,
Commercial Enterprise Solutions,
Since the pandemic began, the diagnostics industry has been
overwhelmingly focused on development and distribution of Covid tests:
faster PCR products, more accurate antigen tests, and more meaningful
antibody assays. In this session, explore what’s next:
- Demand for COVID testing as vaccination expands
- The growing role of antibody tests
- Key questions from providers as they navigate changing diagnostics requirements
Trends in Diagnostics Distribution
Emily Berlin, VP, Product Marketing,
Robert Kovar, Sr. Director,
Marketing & Business Development,
Thermo Fisher Scientific
Erik Ringberg, VP, Lab Category Mgmt.,
Diagnostics manufacturers depend on a strong partnership with distributors to create demand, educate providers, and deliver products to lab customers nationwide. Take part in this candid discussion with lab distributors for insights on:
- Where testing will be delivered, and how to best reach those market segments
- What policy and payment rules are currently driving opportunities for diagnostics growth
- How to build sales and marketing support from your supply chain partners